ES2608829T3 - Inhibidores de tirosina quinasa que contienen diarilacetileno hidrazida - Google Patents

Inhibidores de tirosina quinasa que contienen diarilacetileno hidrazida Download PDF

Info

Publication number
ES2608829T3
ES2608829T3 ES12701370.4T ES12701370T ES2608829T3 ES 2608829 T3 ES2608829 T3 ES 2608829T3 ES 12701370 T ES12701370 T ES 12701370T ES 2608829 T3 ES2608829 T3 ES 2608829T3
Authority
ES
Spain
Prior art keywords
alkyl
ring
aryl
methyl
ethynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12701370.4T
Other languages
English (en)
Spanish (es)
Other versions
ES2608829T8 (es
Inventor
Rajamannar Thennati
Prabal Sengupta
Hemant Ashvinbhai Chokshi
Chetan Surjitsingh Puri
Sabbirhusen Yusufbhai CHIMANWALA
Varun Anilkumar MEHTA
Dipali Manubhai DESAI
Trinadha Rao Chitturi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharma Advanced Research Co Ltd
Original Assignee
Sun Pharma Advanced Research Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Research Co Ltd filed Critical Sun Pharma Advanced Research Co Ltd
Application granted granted Critical
Publication of ES2608829T3 publication Critical patent/ES2608829T3/es
Publication of ES2608829T8 publication Critical patent/ES2608829T8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C241/00—Preparation of compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C241/04—Preparation of hydrazides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/38—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES12701370.4T 2011-01-21 2012-01-23 Inhibidores de tirosina quinasa que contienen diarilacetileno hidrazida Active ES2608829T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN184MU2011 2011-01-21
INMM01842011 2011-01-21
PCT/GB2012/050132 WO2012098416A1 (en) 2011-01-21 2012-01-23 Diarylacetylene hydrazide containing tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
ES2608829T3 true ES2608829T3 (es) 2017-04-17
ES2608829T8 ES2608829T8 (es) 2017-04-27

Family

ID=45540888

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12701370.4T Active ES2608829T3 (es) 2011-01-21 2012-01-23 Inhibidores de tirosina quinasa que contienen diarilacetileno hidrazida

Country Status (12)

Country Link
US (1) US9024021B2 (enExample)
EP (1) EP2665709B1 (enExample)
JP (1) JP5905028B2 (enExample)
KR (1) KR101892574B1 (enExample)
CN (1) CN103502217B (enExample)
AU (1) AU2012208388C1 (enExample)
BR (1) BR112013018212B1 (enExample)
CA (1) CA2825367C (enExample)
EA (1) EA024194B8 (enExample)
ES (1) ES2608829T3 (enExample)
MX (1) MX336051B (enExample)
WO (1) WO2012098416A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013166295A1 (en) 2012-05-02 2013-11-07 Georgetown University Treating neural disease with tyrosine kinase inhibitors
CN103664787B (zh) * 2012-09-17 2015-09-09 南京圣和药业股份有限公司 炔杂芳环化合物及其应用
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
GB2518873A (en) * 2013-10-03 2015-04-08 Agency Science Tech & Res Bicyclic alkyne derivatives and uses thereof
MX2016006325A (es) * 2013-11-15 2016-12-02 Wistar Inst Inhibidores del antígeno nuclear 1 de epstein-barr, y su método de uso.
EP3294705B1 (en) 2015-05-14 2021-07-21 The Wistar Institute Of Anatomy And Biology Ebna1 inhibitors and methods using same
US10150733B2 (en) * 2015-05-18 2018-12-11 Sun Pharma Advanced Research Company Ltd. Amidoheteroaryl aroyl hydrazide ethynes
CN108884066B (zh) * 2016-02-16 2021-08-24 韩国科学技术研究院 作为蛋白激酶抑制剂的2，3，5-取代的噻吩化合物
WO2017208267A1 (en) 2016-06-02 2017-12-07 Sun Pharma Advanced Research Company Limited Treatment for parkinson's disease
EA037697B1 (ru) * 2016-06-02 2021-05-12 Сан Фарма Адвансед Ресёрч Компани Лимитед Лечение болезни паркинсона
CA3056348A1 (en) * 2017-03-15 2018-09-20 Sun Pharma Advanced Research Company Limited Novel amorphous dispersion of 4-methyl-3-quinolin-3-ylethynyl-benzoic acid n'-(2-chloro-6-methyl-benzoyl) hydrazide
MA47798A (fr) 2017-03-15 2020-01-22 Sun Pharma Advanced Res Co Ltd Nouvelle dispersion amorphe d'acide cyclopropanecarboxylique (5-{5-[ n'-(2-chloro-6-méthylbenzoyl) hydrazinocarbonyl] -2-méthyl-phényléthynyl}-pyridin-2-yl) amide
WO2019222470A1 (en) 2018-05-17 2019-11-21 The Wistar Institute Ebna1 inhibitor crystalline forms, and methods of preparing and using same
CN113272308B (zh) 2018-11-20 2025-03-18 乔治敦大学 用于治疗神经退行性、肌退行性和溶酶体贮积病症的组合物和方法
BR112021024835A2 (pt) 2019-06-11 2022-01-18 Sun Pharma Advanced Res Co Ltd Tratamento para sinuclenopatias
MX2022007988A (es) 2019-12-26 2022-07-11 Beijing Innocare Pharma Tech Co Ltd Formas cristalinas de (s)-1-(1-acriloilpirrolidin-3-il)-3-((3,5-di metoxifenil)etinil)-5-(metilamino)-1h-pirazol-4-carboxamida.
CN115279759B (zh) 2020-02-28 2025-07-29 大邱庆北尖端医疗产业振兴财团 苯甲酰胺衍生物及其制备方法和用途
IL300044A (en) 2020-07-31 2023-03-01 Sun Pharma Advanced Res Co Ltd N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl) ethynyl]-benzohydrazide for treatment of alzheimer's disease
TW202317530A (zh) 2021-06-29 2023-05-01 日商住友化學股份有限公司 雜環化合物及含有其之組成物之抗藥性有害節肢動物防除方法
CN120018848A (zh) 2022-08-25 2025-05-16 太阳医药高级研究有限公司 使用酪氨酸激酶抑制剂沃多巴替尼治疗慢性髓细胞白血病的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
NZ513639A (en) 1999-04-15 2004-02-27 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
MXPA02010231A (es) * 2001-11-27 2004-12-13 Warner Lambert Co Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
ES2332184T3 (es) * 2004-03-22 2010-01-28 ELI LILLY & COMPANY Derivados de piridilo y su uso como antagonistas del receptor mglu5.
SI1973545T1 (sl) * 2005-12-23 2013-04-30 Ariad Pharmaceuticals, Inc. Spojine bicikličnega heteroarila
DK1973545T3 (da) * 2005-12-23 2013-02-25 Ariad Pharma Inc Bicykliske heteroarylforbindelser
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
WO2009100536A1 (en) * 2008-02-15 2009-08-20 Methylgene Inc. Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures

Also Published As

Publication number Publication date
KR20140016889A (ko) 2014-02-10
AU2012208388C1 (en) 2017-04-27
US9024021B2 (en) 2015-05-05
AU2012208388A1 (en) 2013-08-22
AU2012208388B2 (en) 2017-01-05
AU2012208388A2 (en) 2013-08-22
EA024194B8 (ru) 2016-11-30
EA201370166A1 (ru) 2014-05-30
ES2608829T8 (es) 2017-04-27
JP2014510037A (ja) 2014-04-24
KR101892574B1 (ko) 2018-08-28
WO2012098416A1 (en) 2012-07-26
CN103502217A (zh) 2014-01-08
US20130296557A1 (en) 2013-11-07
EA024194B1 (ru) 2016-08-31
EP2665709B1 (en) 2016-12-07
EP2665709A1 (en) 2013-11-27
BR112013018212B1 (pt) 2021-12-14
MX336051B (es) 2016-01-07
BR112013018212A2 (pt) 2020-12-29
CA2825367A1 (en) 2012-07-26
MX2013008296A (es) 2014-03-21
CN103502217B (zh) 2015-11-25
CA2825367C (en) 2018-09-25
JP5905028B2 (ja) 2016-04-20

Similar Documents

Publication Publication Date Title
US9024021B2 (en) Diarylacetylene hydrazide containing tyrosine kinase inhibitors
ES2393130T3 (es) Triazoles bicíclicos como moduladores de proteínas quinasas
TW202039489A (zh) Mat2a之雜雙環抑制劑及用於治療癌症之使用方法
CN112724145A (zh) 用于抑制shp2活性的吡嗪衍生物
CN112839937B (zh) 异吲哚啉-1-酮衍生物、其制备方法及其用途
CN102399220A (zh) 三并环类PI3K和mTOR双重抑制剂
JP7477846B2 (ja) Ｎを含むヘテロアリール誘導体およびこれを有効成分として含むがんの予防または治療用薬学的組成物
EP2942349A1 (en) Enzyme modulators and treatments
WO2014040549A1 (zh) 炔杂芳环化合物及其应用
EP1268487B1 (en) Tricyclic protein kinase inhibitors
ES2945573T3 (es) Compuesto de dioxazolina, método de preparación y usos del mismo
KR101350006B1 (ko) 피리돈 유도체를 포함하는 단백질 키나제 억제제
CN109761899B (zh) 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物
CN107074778A (zh) 苯并咪唑类似物和相关方法
EA018716B1 (ru) Новые 4-(тетразол-5-ил) хиназолиновые производные в качестве противораковых средств
KR19990082201A (ko) 에이즈 치료제 또는 예방제
CN110156782A (zh) 作为pi3k/mtor抑制剂的吡啶基取代的稠合喹啉化合物
CN121925419A (zh) 一种吡啶-2(1h)-酮类prmt5-mta抑制剂、其药物组合物及其应用
US11407760B2 (en) Dioxinoquinoline compounds, preparation method and uses thereof
KR102046196B1 (ko) 이미다조피리딘 유도체의 치료적 용도
CN105541792B (zh) 多环类pi3k抑制剂
AU2020374269A1 (en) Novel heterocyclic-substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect, and pharmaceutical composition containing same
HK40118749A (zh) 作为pi3k抑制剂的苯并嘧啶-4(3h)-酮
HK40083035B (zh) Parp7抑制剂及其用途
WO2014154026A1 (zh) PI3K和/或mTOR抑制剂的前药